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Tadayuki Kobayashi, MSc4; Kenji Ishii, MD3; Keiichi Oda, PhD3; Kiichi Ishiwata, PhD3; Willem Vaalburg, PhD1;
and Philip H. Elsinga, PhD1
1PET Center, Groningen University Hospital, Groningen, The Netherlands; 2Department of Medical Oncology, Groningen University
Hospital, Groningen, The Netherlands; 3Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; and 4M’s Science, Kobe, Japan
Our objective was to study 2 radioligands for visualization of
-receptors with PET. Methods: Two radioligands—1-selec-
tive 11C-1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)pipera-
zine (11C-SA4503) and nonsubtype-selective 1-(4–2-18F-fluoro-
ethoxy-3-methoxyphenethyl)-4-(3-(4-fluorophenyl)propyl)piperazine
(18F-FE-SA5845)—were evaluated for tumor imaging. Results:
Binding studies to rat glioma cells (C6) and human nonsmall cell
lung cancer cells (N417) indicated interaction of 18F-FE-SA5845
with 2 sites and interaction of 11C-SA4503 with a single site.
Specific binding of 18F-FE-SA5845 was 93%  2% and that of
11C-SA4503 was 78%  6% of the total cellular uptake of
radioactivity. Uptake of the 18F-labeled ligand, but not that of the
11C-labeled ligand, appeared to be related to the growth phase
of the cells. Biodistribution experiments in C6 tumor-bearing
nude rats (Ham HSD RNU rnu) indicated tumor-to-plasma ratios
of 13.3 for 11C-SA4503 and 8.0 for 18F-FE-SA5845 and tumor-
to-muscle ratios of 5.0 for 11C-SA4503 and 4.9 for 18F-FE-
SA5845, 60 min after injection, which were reduced to values
ranging from 1.4 to 2.0 after pretreatment of animals with halo-
peridol (2 mol/kg). Tumor uptake of 18F-FE-SA5845 showed a
negative correlation with tumor size (P  0.0001), in contrast to
that of 11C-SA4503, suggesting that tissue binding of the former
ligand is related to cellular proliferation. A study with 11C-
SA4503 in a human volunteer indicated high uptake in liver,
kidney, and heart but relatively low background in thorax and
lower abdomen. Conclusion: Both 18F-FE-SA5845 and 11C-
SA4503 demonstrate specific binding to -receptors in vivo and
may be useful for the detection of pulmonary and abdominal
tumors. However, the 18F-labeled compound may be better for
tumor staging than the 11C-labeled drug.
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The most widely used radiopharmaceutical in clinical
oncology is 18F-FDG. Although the applications of 18F-FDG
PET in tumor detection, staging, and therapy evaluation are
rapidly expanding, 18F-FDG uptake is not tumor specific.
Various forms of inflammatory lesions also take up 18F-
FDG and are a major cause of false-positive results. A
decreased uptake of 18F-FDG is seen in hyperglycemic
patients, which can cause false-negative scan data. Because
of the urinary excretion of 18F-FDG, tumors in the lower
abdomen (e.g., prostate tumors) are relatively poorly visu-
alized. Thus, there is opportunity for the development of
novel tumor imaging agents that may lack some of the
disadvantages of 18F-FDG.
-Receptors are unique proteins with a high affinity for
neuroleptics such as haloperidol (1). They are strongly
overexpressed in a large variety of human tumors—for
example, glioma, neuroblastoma, melanoma, and breast
cancer (2–4). The endogenous ligands for these sites have
not yet been identified, although neuroactive steroids such
as progesterone have a high affinity for -receptors (5,6).
Two subtypes of the -receptor have been discerned: 1
and 2, based on their opposite enantioselectivity for ben-
zomorphans and different molecular masses (7). The 2-
receptor density of tumors is a biomarker of cellular prolif-
eration (8–10). Activation of intracellular 2-receptors
increases cytosolic Ca2 and induces apoptosis via a
caspase- and p53-independent mechanism (1,11,12). There-
fore, -agonists may be effective antineoplastic agents and
chemosensitizers (12–14)
A radioligand for visualization of -receptors with PET
could be useful for (a) selective detection of primary tumors
and their metastases, (b) noninvasive assessment of tumor
proliferative status, and (c) measurement of the -receptor
occupancy of novel and established antineoplastic drugs.
We have evaluated 2 radioligands for these purposes.
SA4503 has a relatively high affinity for 1-receptors
(50% inhibitory concentration [IC50], 17.4 nmol/L) but neg-
ligible affinity for the 2-subtype (IC50, 1,784 nmol/L) and
for 36 other neuroreceptors, ion channels, and second mes-
senger systems (15). In contrast, its fluoroethyl analog,
FE-SA5845, has a high affinity to both 1- and 2-receptors
(IC50 values, 3.1 and 6.8 nmol/L, respectively) (16). The
lipophilicity of both drugs is about optimal for entry of the
central nervous system (log P values, 2.5 and 2.7,
respectively) (16,17). In fact, 11C-SA4503 has been success-
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fully used for PET studies of -receptors in cat, monkey,
and human brain (18–21). Monkey studies with 18F-FE-
SA5845 have also been performed (22).
Here, we report the results of in vitro and in vivo exper-
iments in which 18F-FE-SA5845 and 11C-SA4503 were
evaluated for tumor imaging. 18F-FE-SA5845 offers the
advantages of a longer half-life of the radionuclide (109.8
min for 18F vs. 20.3 min for 11C) and a high affinity to
2-receptors, which are the major subtype in tumor cells (3).
In vivo assays of 2-receptor density may allow tumor
staging (8–10). Since not only 2-receptors but also 1-
receptors are present in most tumors (3) and the relationship
between 1-receptor density and proliferative status is un-
known, 11C-SA4503 could also be a successful imaging
agent.
MATERIALS AND METHODS
Culture Media and Drugs
()-Pentazocine and (S)-()-raclopride were purchased from
Research Biochemicals International. Haloperidol was a product of
Sigma. Unlabeled SA4503 was a gift from Santen Pharmaceutical
Co. (S)-Ketamine (Ketanest) was purchased from Parke-Davis;
Matrigel Basement Membrane Matrix was from BD Biosciences;
and Dulbecco’s Minimum Essential Medium (DMEM), fetal calf
serum (FCS), and trypsin were from Invitrogen.
Radioligands
18F-FE-SA5845 and 11C-SA4503 were prepared by reaction of
18F-fluoroethyl tosylate and 11C-methyl iodide, respectively, with
the appropriate 4-O-demethyl compound, as described previously
(16,17). The decay-corrected radiochemical yields of 18F-FE-
SA5845 and 11C-SA4503 were 4%–7% and 9%–11%, respec-
tively. Synthesis times were 80 and 45 min, respectively. The
specific radioactivities of 18F-FE-SA5845 and 11C-SA4503 were
74 and 10 TBq/mmol at the time of injection. Radiochemical
purities were 95%.
Cell Culture
C6 rat glioma cells obtained from the American Type Culture
Collection were cultured in monolayers in DMEM supplemented
with 5% FCS in a humidified atmosphere of 5% CO2/95% air at
37°C. Before each experiment, C6 cells were seeded in 12-well
plates (Costar) with 1.5 mL of DMEM supplemented with 5% FCS
per well. After 24 h at 37°C, monolayers had grown.
N417 human nonsmall cell lung cancer cells were grown in
suspension in 25-cm2 plastic flasks (Corning Co.) and cultured in
DMEM with 10% FCS. After harvesting by centrifugation and
resuspending in fresh medium, 1-mL samples of cell suspension in
15-mL test tubes were used for binding studies. All incubations
were performed at 37°C in a shaking waterbath (Heidolph).
Binding Studies: C6 Cells
Binding studies to C6 rat glioma cells were performed in
monolayers grown at the bottom of 12-well plates. In competition
studies, various concentrations of an unlabeled competitor (halo-
peridol, ()-pentazocine, raclopride, or ketamine; range, 1012 to
103 mol/L) were dispensed to the culture medium in the wells. At
time zero, 2 MBq of radioligand in 50 L of saline were added to
each well. At the end of incubation (60 min), the medium was
quickly removed and the monolayer was washed 3 times with
phosphate-buffered saline (PBS). Cells were then treated with 0.25
mL of trypsin. When the cells had detached from the bottom of the
well, 1 mL of DMEM was added to stop the proteolytic action.
Cell clumps were removed by repeated (at least 10-fold) pipetting
of the trypsin/DMEM mixture. Radioactivity in the cell suspension
(1.2 mL) was assessed using a 	-counter (Compugamma 1282 CS;
LKB-Wallac). A 50-L sample of the suspension was mixed with
50 L of trypan blue (0.4% solution in PBS) and used for cell
counting. Cell numbers were manually determined, using a phase-
contrast microscope (Zeiss), a Bu¨rker bright-line chamber (depth,
0.1 mm; 0.0025-mm2 squares), and a hand-tally counter. Nonspe-
cific binding of the radioligand was defined as residual binding to
the cells in the presence of an unlabeled competitor (5 
 104
mol/L ()-pentazocine, haloperidol, or unlabeled SA4503).
To study the influence of cell density on ligand binding, differ-
ent numbers of C6 cells were seeded in various wells. After 1–4 d
of growth in 12-well plates, cell densities ranged from 55,000 to
2,600,000 cells per well. Two megabecquerels of 18F-FE-SA5845
or 11C-SA4503 in 50 L of saline were then added. At the end of
incubation (60 min), medium was quickly removed. Cells were
washed, trypsinized, and counted as described.
Binding Studies: N417 Cells
Binding studies to N417 cells were performed in test tubes
containing a suspension of 106 cells/mL. In competition studies,
various concentrations of an unlabeled competitor (haloperidol,
()-pentazocine, ketamine, or SA4503; range, 1012 to 103
mol/L) were dispensed to the culture medium in the tubes. At time
zero, 2 MBq of radioligand in 50 L saline were added to each
tube. At the end of incubation (60 min in most studies), the cells
were harvested by centrifugation (10 s in a Hettich Micro 20
centrifuge at maximum speed, 14,000g). The cells were washed 3
times by resuspending them in PBS followed by repeated centri-
fugation. Removal of cell clumps, radioactivity, and cell counting
were then performed as described.
Biodistribution Experiments
The experiments were performed by licensed investigators in
accordance with the Law on Animal Experiments of The Nether-
lands (“Wet op de Dierproeven” 1977  Amendments 1996,
“Dierproevenbesluit” 1985  Amendments 1996). Female nude
rats (HSD Ham RNU rnu; 150–200 g body weight) were obtained
from Harlan. After 1 wk of acclimatization, C6 glioma cells (2.5

106, in a 1:1 v/v mixture of Matrigel and DMEM containing 5%
FCS) were subcutaneously injected into both flanks. Matrigel was
included to avoid migration of tumor cells to other sites than the
place of injection. Biodistribution studies were done after 9–10 d,
when solid tumor nodules of 0.7- to 1.7-cm diameter had grown.
The rats were anesthetized using sodium pentobarbital (60
mg/kg intraperitoneal). Animals were kept under anesthesia for the
rest of the experiment. The radiopharmaceutical (10 MBq 18F-FE-
SA5845 or 20 MBq 11C-SA4503) was intravenously administered
through a cannula inserted into a lateral tail vein. In blocking
experiments, haloperidol (2 mol/kg in saline containing 10%
ethanol) was administered 2 min before injection of the radioli-
gand, through the same cannula, whereas control rats received
saline only. The animals were sacrificed 60 min after radiotracer
injection by extirpation of the heart (under general pentobarbital
anesthesia). Blood was collected and normal tissues (brain, fat,
bone, heart, intestines, kidney, liver, lung, skeletal muscle, pan-
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creas, spleen, submandibular gland, and urinary bladder) were
excised. Urine was collected and plasma plus a red cell fraction
were obtained from blood centrifugation (5 min at 1,000g). The
complete tumor was excised and carefully separated from muscle
and skin. All samples were weighed, and the radioactivity was
measured using the 	-counter, applying a decay correction. The
results are expressed as dimensionless standardized uptake values
(SUVs): cpm measured per gram of tissue/cpm injected per gram
of body weight. Tumor-to-plasma and tumor-to-muscle concentra-
tion ratios of radioactivity were also calculated.
Statistical Analysis
Statistical analysis was performed using the software package
Statistix (NH Analytic Software). Differences between the various
groups (control and haloperidol pretreated) were tested for statis-
tical significance using the 2-sided Student t test for independent
samples. P  0.05 was considered significant.
Human Study
A pilot study with 11C-SA4503 was performed on a volunteer.
The study was approved by the Ethical Committee of the Tokyo
Metropolitan Institute of Gerontology. A female subject (76 y old,
45.5 kg, 157.3 cm) participated, after written informed consent had
been obtained. She had no clinical abnormality. The PET camera
used was a SET-2400W type having an axial field of view of 20
cm (Shimadzu Co.) (23). Thirty-one minutes after intravenous
injection of 11C-SA4503 (560 MBq/9.7 nmol) into the subject, a
whole-body scan, spanning from head to legs, was performed in
2-dimensional mode (5 overlapping bed positions, 7-min emission
time per position, with attenuation correction). Data were recon-
structed using an ordered-subsets expectation maximization
method (subsets, 16; iterations, 2). Pixel counts of the whole-body
image were calibrated to activity concentration (Bq/mL).
RESULTS
Binding Studies in Tumor Cells
Initial in vitro studies showed rapid association of 18F-
FE-SA5845 and 11C-SA4503 with tumor cells, equilibrium
being reached after 20 min of incubation and remaining for
120 min at 37°C (values not shown). Therefore, an incu-
bation time of 60 min was used in all subsequent experi-
ments (24).
Competition studies using the 1-subtype–selective ago-
nist ()-pentazocine indicated binding of 18F-FE-SA5845
to 2 sites, both in the rodent and human cells. Biphasic
competition was also observed for the nonsubtype-selective
-ligand haloperidol (Table 1). The N-methyl-D-aspartate
(NMDA) antagonist (S)-ketamine (which is often used for
rodent anesthesia) and the dopamine D2-receptor antagonist
(S)-()-raclopride inhibited the binding of 18F-FE-SA5845
only at high concentrations (IC50 values in the 105 to 104
mol/L range; Table 1).
In contrast to 18F-FE-SA5845, ()-pentazocine competi-
tion indicated binding of 11C-SA4503 to a single site, both
in C6 and N417 cells. Monophasic inhibition of 11C-
SA4503 binding was also observed in experiments using
haloperidol and unlabeled SA4503 (Table 1). The NMDA
antagonist (S)-ketamine inhibited the binding of 11C-
SA4503 only at high concentrations (IC50 values in the 105
to 104 mol/L range; Table 1).
When 18F-FE-SA5845 was added to cells that either were
actively growing or had become confluent, the equilibrium
binding of the radioligand was found to be dependent on the
growth phase. Rapidly growing cells showed a high uptake
of 18F, but uptake in confluent cells was 5-fold reduced
TABLE 1





(human small cell lung carcinoma)
IC50 R IC50 R
18F-FE-SA5845*
()-Pentazocine (1) (0.3 nmol/L)/(13 mol/L) 0.987 (4.6 nmol/L)/(10 mol/L) 0.996
Haldol (1, 2, D2, D3) (12 nmol/L)/(3.5 mol/L) 0.999 (0.1 mol/L)/(6.5 mol/L) 0.996
Raclopride (D2) 200 mol/L 0.991 27 mol/L 0.995
(S)-Ketamine (NMDA) ND ND 52 mol/L 0.998
11C-SA4503†
()-Pentazocine (1) 2.4 mol/L 0.957 8.6 mol/L 0.982
Haldol (1, 2, D2, D3) 0.1 mol/L 0.997 0.3 mol/L 0.994
SA4503 (1) 0.2 mol/L 0.998 ND ND
(S)-Ketamine (NMDA) 22 mol/L 0.998 45 mol/L 0.998
*Specific (haloperidol and ()-pentazocine sensitive) binding of tracer as fraction of total uptake: 93.2%  2.2%.
†Specific (pentazocine, haloperidol, and SA4503 sensitive) binding of tracer as fraction of total uptake: 78.3%  6.0%.
R  correlation coefficient of curve fit; ND  not determined.
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(Fig. 1). Different results were obtained with 11C-SA4503.
Uptake of this tracer in confluent cells was only slightly
(2-fold) reduced compared with that of actively growing
cells (Fig. 1).
Biodistribution of 18F-FE-SA5845
After injection of 18F-FE-SA5845 in tumor-bearing rats,
the highest uptake of radioactivity was observed in liver,
followed by kidney, pancreas, and lung. Submandibular
gland, intestines, spleen, urinary bladder, brain, and C6
tumor showed moderate tracer uptake, whereas low levels
of radioactivity were found in heart, adipose tissue, bone,
muscle, plasma, and red blood cells (Table 2).
Pretreatment of animals with haloperidol (2 mol/kg)
caused a strong reduction of tissue uptake in brain, intes-
tines, kidney, liver, and C6 tumors, whereas radioactivity in
plasma and blood cells was increased. Radioactivity in
spleen and submandibular gland seemed also to be de-
creased by haloperidol, but statistical significance (P 
0.05) was not reached in these organs because of a relatively
high interindividual variation. Control animals showed tu-
mor-to-plasma and tumor-to-muscle ratios of 8.0 and 4.9,
respectively, at 60 min after injection. These were reduced
to low values (1.4–1.5) in pretreated rats (Table 2).
Biodistribution of 11C-SA4503
The 1-subtype–selective radioligand 11C-SA4503
showed a biodistribution similar to that of nonsubtype-
selective 18F-FE-SA5845. The highest uptake of radioactiv-
ity was observed in liver, followed by pancreas, small
intestine, and kidney. Moderate tracer uptake was found in
spleen, submandibular gland, large intestine, lung, urinary
bladder, and the C6 tumor. Low uptake of 11C was observed
in heart, bone, adipose tissue, muscle, plasma, and red blood
cells (Table 3). Uptake of 11C in C6 tumors after injection of
11C-SA4503 tended to be lower than the uptake of 18F after
administration of 18F-FE-SA5845 (SUV values in Table 2
compared with those in Table 3).
Pretreatment of animals with haloperidol (2 mol/kg)
suppressed the uptake of 11C-SA4503 in target tissues. A
reduction of tissue radioactivity was observed in brain,
intestines, kidney, liver, and C6 tumors, whereas radioac-
tivity in plasma, red blood cells, and myocardium was
increased. However, radioactivity levels in spleen and sub-
mandibular gland were not reduced after haloperidol pre-
treatment.
Although tumor SUVs of 11C-SA4503 appeared to be
lower than those of 18F-FE-SA5845, similar target-to-non-
target ratios were measured for the 2 tracers. Control ani-
mals showed tumor-to-plasma ratios of 13.3 and tumor-to-
muscle ratios of 5.0, 60 min after injection of 11C-SA4503.
TABLE 2
Biodistribution of 18F-FE-SA5845 in Tumor-Bearing Rats





(n  5) P
Cerebellum 1.41  0.23 0.43  0.12 0.0001
Cerebral cortex 1.26  0.31 0.45  0.16 0.0005
Rest brain 1.42  0.28 0.41  0.13 0.0001
Adipose tissue 0.46  0.18 0.45  0.26 NS
Bladder 1.61  0.94 0.95  0.45 NS
Bone 0.42  0.14 0.39  0.13 NS
Heart 0.47  0.16 0.66  0.25 NS
Large intestine 1.76  0.18 0.84  0.30 0.0002
Small intestine 2.35  0.44 1.13  0.35 0.0006
Kidney 4.95  0.84 1.77  0.58 0.0001
Liver 9.28  1.50 5.58  2.24 0.01
Lung 2.93  0.83 2.50  1.09 NS
Muscle 0.20  0.07 0.25  0.10 NS
Pancreas 4.23  0.85 4.39  2.69 NS
Plasma 0.12  0.03 0.23  0.05 0.001
Red blood cells 0.08  0.01 0.16  0.05 0.05
Spleen 2.05  0.46 1.43  0.53 0.08
Submandibular 2.33  0.85 1.31  0.73 0.06
C6 tumor* 0.92  0.39 0.37  0.18 0.0005
Urine 9.71  6.54 9.45  3.88 NS
Tumor/plasma* 8.0  3.2 1.4  0.9 0.0001
Tumor/muscle* 4.9  2.8 1.5  0.9 0.001
*Twice as much data (2 n) since each rat had 2 tumors.
NS  not significant.
SUVs (and dimensionless ratios) are listed (mean  SD).
FIGURE 1. Relationship between growth
stage (number of C6 cells per well) and
cellular uptake of 18F-FE-SA5845 (A) and
11C-SA4503 (B). Ordinate indicates total
bound radioactivity within cells. Dashed
line is an exponential curve fit.
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These were reduced to low values (1.9–2.0) in pretreated
rats (Table 3).
Size-Dependent Tracer Uptake
When tracer binding in individual tumors was plotted
against tumor mass, the uptake of 18F-FE-SA5845 was
found to be negatively correlated with tumor size (slope,
0.85  0.10; r  0.95, P  0.0001; Fig. 2). Different
results were observed for the in vivo uptake of 11C-SA4503.
The uptake of this tracer did not show a significant rela-
tionship with tumor size (slope, 0.04  0.12; r  0.14,
P  not significant; Fig. 2).
Human Study
The human pilot study with 11C-SA4503 in a single
volunteer (Fig. 3) indicated high uptake of the tracer in
brain, heart, liver and kidneys, but a relatively low back-
ground of radioactivity in the thorax, extremities, and lower
abdomen.
DISCUSSION
This study confirms that the nonsubtype-selective ligand
18F-FE-SA5845 binds to 2 sites and the 1-subtype–selec-
tive ligand 11C-SA4503 binds to a single site in intact tumor
cells (Table 1). Probably, the 2 binding sites of 18F-FE-
SA5845 are 1- and 2-receptors. In vitro competition ex-
periments with the established 1-receptor agonists ()-
pentazocine and SA4503, or the -receptor antagonist
haloperidol, indicated that the specific binding of 18F-FE-
SA5845 was 93%  2% and of 11C-SA4503 was 78% 
6% of the total cellular uptake of radioactivity, both in
rodent and human cells (Table 1). Thus, the in vitro exper-
iments suggest better signal-to-noise ratios for 18F-FE-
SA5845 than for 11C-SA4503. 18F-FE-SA5845 and 11C-
TABLE 3
Biodistribution of 11C-SA4503 in Tumor-Bearing Rats





(n  3) P
Cerebellum 1.06  0.38 0.58  0.05 0.05
Cerebral cortex 1.24  0.47 0.45  0.01 0.02
Rest brain 1.27  0.40 0.48  0.03 0.01
Adipose tissue 0.21  0.07 0.68  0.33 NS
Bladder 1.01  0.69 0.87  0.38 NS
Bone 0.27  0.19 0.24  0.14 NS
Heart 0.30  0.09 0.69  0.16 0.005
Large intestine 1.59  0.24 0.70  0.16 0.002
Small intestine 2.92  0.91 0.89  0.29 0.01
Kidney 2.89  0.24 1.39  0.07 0.0001
Liver 11.61  2.28 4.81  1.25 0.005
Lung 1.55  0.30 1.60  0.24 NS
Muscle 0.19  0.11 0.22  0.02 NS
Pancreas 5.04  4.39 3.40  1.26 NS
Plasma 0.06  0.02 0.24  0.04 0.0001
Red blood cells 0.06  0.03 0.13  0.01 0.01
Spleen 2.43  0.71 3.32  0.42 NS
Submandibular 2.36  0.77 3.78  0.14 NS
C6 tumor* 0.65  0.15 0.43  0.15 0.05
Urine 4.02  2.86 7.29  2.80 NS
Tumor/plasma* 13.3  3.1 1.9  0.9 0.0001
Tumor/muscle* 5.0  2.5 2.0  0.7 0.05
*Twice as much data (2 n) since each rat had 2 tumors.
NS  not significant.
SUVs (and dimensionless ratios) are listed (mean  SD).
FIGURE 2. Relationship between tumor
mass (in vivo C6 tumors grown in nude
rats) and tumor uptake of 18F-FE-SA5845
(A) and 11C-SA4503 (B). Solid and open
symbols are data points of individual tu-
mors; dashed line is result of a linear re-
gression analysis.
FIGURE 3. Whole-body scan
of human volunteer, made
31– 66 min after injection of
11C-SA4503.
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SA4503 do not bind to dopamine D2-receptors or NMDA
receptors on intact tumor cells, since the D2/D3-receptor
antagonist raclopride and the NMDA antagonist (S)-keta-
mine inhibited the binding only at high concentrations (105
to 103 mol/L range).
Experiments in which the effect of the growth phase on
the cellular uptake of the -ligands was examined indicated
a marked decline in the uptake of 18F-FE-SA5845, but a less
marked decline in 11C-SA4503 uptake, in confluent cells
(Fig. 1). 11C-SA4503 is selective for the 1-subtype,
whereas 18F-FE-SA5845 binds equally well to 1- and 2-
receptors. Figure 1 is therefore in accordance with reports in
the literature which suggest that the density of 2-receptors
is related to the proliferative status of tumor cells (8–10).
Using another cell line (66 cells rather than C6 cells), Mach
et al. have shown that the 2-receptor density is 10-fold
reduced in quiescent cells (8).
In biodistribution experiments (Tables 2 and 3), both
18F-FE-SA5845 and 11C-SA4503 showed specific (i.e., halo-
peridol sensitive) binding in C6 tumors and also in other
target organs, such as brain, intestines, kidney, and liver.
The high and haloperidol-sensitive uptake of 18F-FE-
SA5845 and 11C-SA4503 in liver, kidney, and intestines is
consistent with the reported high levels of 1-receptor mes-
senger RNA (25,26) and high densities of 1- and 2-
receptors in these excretory organs (27–30). Although both
1- and 2-receptors have been reported to be expressed on
splenocytes (31,32), only 18F-FE-SA5845 showed some
specific binding in rat spleen (Table 2). Apparently, the
1-subtype–specific radioligand ‘11C-SA4503 shows high
nonspecific and little specific binding in rat spleen in vivo.
The biodistribution experiments indicated tumor-to-
plasma ratios of 13.3 for 11C-SA4503 and 8.0 for 18F-FE-
SA5845 and tumor-to-muscle ratios of 5.0 for 11C-SA4503
and 4.9 for 18F-FE-SA5845, 60 min after injection, which
were reduced to values ranging from 1.4 to 2.0 after pre-
treatment of animals with haloperidol (Tables 2 and 3).
These tumor-to-plasma ratios are higher than or equal to
those of the radiopharmaceuticals 18F-FDG and 3-deoxy-
3-18F-fluorothymidine (18F-FLT), which were studied pre-
viously in the same in vivo tumor model (6.1 and 3.8,
respectively) (33). The observed tumor-to-muscle ratios of
the -ligands are also higher than those of 18F-FLT (3.8 
1.4) but lower than those of 18F-FDG (13.2  3.0) (33).
Tumor uptake of the 18F-labeled ligand tended to be
higher than that of the 11C-labeled agonist (SUV, 0.92 
0.39 vs. 0.65  0.16, respectively; Tables 2 and 3). This
trend is probably due to the fact that 18F-FE-SA5845 binds
to both 1- and 2-receptors (16), whereas 11C-SA4503
interacts with 1-receptors only (15).
Another difference between the 2 radiotracers was ob-
served when the SUV in individual tumors was plotted
against tumor mass (Fig. 2). The SUV of 18F-FE-SA5845
was negatively correlated with tumor size (P  0.0001), in
contrast to tissue uptake of 11C-SA4503. All tumors in these
experiments showed only small areas of necrosis, amount-
ing to10% of the total tumor volume. Thus, the decline in
the SUV of 18F-FE-SA5845 with increasing tumor size was
not related to necrosis. Perfusion changes with increasing
tumor size should have affected the uptake of both radioli-
gands equally, since they have similar lipophilicities and the
range of tumor sizes was similar in both cases (Fig. 2).
Although no data on growth rate are available, the most
likely explanation for the different behavior of the 2 ligands
is that only the binding of 18F-FE-SA5845 is related to
cellular proliferation.
The human pilot study with 11C-SA4503 indicated a
relatively low background level of radioactivity in the ex-
tremities, thorax, and lower abdomen. Thus, 11C-SA4503
may be useful for the detection of sarcomas, lung tumors
and abdominal tumors, using PET.
CONCLUSION
18F-FE-SA5845 and 11C-SA4503 demonstrate specific
binding to -receptors, both in vitro and in vivo. The
observed target-to-nontarget ratios suggest that these radio-
ligands may be suitable for tumor detection and for assess-
ment of the -receptor occupancy of novel therapeutic
drugs. The uptake of 18F-FE-SA5845 was reduced in large
tumors and quiescent cells, in contrast to the binding of
11C-SA4503. Hence, 18F-FE-SA5845 may be preferred over
11C-SA4503 for tumor staging.
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